EGFR and non-small cell lung carcinoma: Furthermore, osimertinib is expected to have good central nervous system translocation and a limited inhibition of the wild-type EGFR, which may make it less toxic, and therefore, the first choice for EGFR-mutated NSCLC [16,17,18].